References

American Cancer Society. Cancer Facts & Figures 2004. Atlanta, Ga: American Cancer Society Inc; 2004. Also available online. 

Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.

Andre T, Figer A, Cervantes A, et al. FOLFOX7 compared to FOLFOX4. Preliminary results of the randomized optimox study. Proc Am Soc Clin Oncol. 2003;22:253. Abstract 1016.

Arnell TD, Stamos MJ. Alternatives in therapy for low rectal cancer. Journal of Wound, Ostomy and Continence Nursing. 1996:23:150-153.

Benson AB, Catalano PJ, Meropol NJ, et al. Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): an interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study ES3200. Proc Am Soc Clin Oncol. 2003;22:243. Abstract 975.

Bishop DT, Hall NR. The genetics of colorectal cancer. Eur J Cancer. 1994;30A:1946-1956.

Brown KA, Esper P, Kelleher LO, O’Neill JEB, Polovich M, White JM, eds. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. Pittsburgh, Pa: Oncology Nursing Society; 2001.

Cassidy J, Tabernero J, Twelves C, et al. XELOX (Capecitabine Plus Oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22:2084-2091.

Colditz GA, Atwood KA, Emmons K, et al. Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index. Risk Index Working Group, Harvard Center for Cancer Prevention. Cancer Causes Control. 2000;11:477-488.

Cunningham D, Humlet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.

de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15:808-815.

de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.

de Gramont A, Cervantes A, Andre T, et al. OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol. 2004;23:251. Abstract 3525.

Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-1047.

Fuchs CS, Giovannucci EL, Colditz GA, et al. A prospective study of family history and the risk of colorectal cancer. N Engl J Med. 1994;331:1669-1674.

Fyfe GA, Hurwitz H, Fehrenbacher L, et al. Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. J Clin Oncol. 2004;22(suppl 14s):274s. Abstract 3617.

Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004;10:4055-4061.

Giantonio BJ, Chen HX, Catalano PJ, et al. Bowel perforation and fistula formation in colorectal caner patients treated on Eastern Cooperative Oncology Group (ECOG) studies E2200 and E3200. J Clin Oncol. 2004;22(suppl 14s):199s. Abstract 3017.

Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004:22:23-30.

Grothey A, Jordan K, Kellner O, et al. Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer. Proc Am Soc Clin Oncol. 2003;22:255. Abstract 1022.

Hambleton J, Novotny WF, Hurwitz H, et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. J Clin Oncol. 2004;22(suppl 14s):252s. Abstract 3528.

Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282-2292.

Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.

Lenz HJ, Mayer RJ, Gold PJ, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. J Clin Oncol. 2004;22(suppl 14s):247s. Abstract 3510.

Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425.

Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998;16:301-308.

MUSC Health Connection, 1-800-424-MUSC or 843-792-1414. http://www.muschealth.com.

NCCN Clinical Practice Guidelines in Oncology™—Colon Cancer v.2.2004, 04/30/04.

Novotny WF, Holmgren E, Nelson B, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) does not increase the incidence of venous thromboembolism when added to first-line chemotherapy to treat metastatic colorectal cancer. J Clin Oncol. 2004;22(suppl 14s):252s. Abstract 3529.

Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol. 2001;19:3801-3807.

Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-914.

Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). J Clin Oncol. 2004;22(suppl 14s):245s. Abstract 3500.

Scappaticci F, Fehrenbacher L, Cartwright T, et al. Lack of effect of bevacizumab on wound healing/bleeding complications when given 28-60 days following primary cancer surgery. Proc Am Soc Clin Oncol. 2004;23:253. Abstract 3530.

Smith RE, Colangelo L, Wieand S, et al. The occurrence of severe enteropathy among patients with stage I/III resected colon cancer (CC) treated with 5-FU leucovorin (FL) plus oxaliplatin (FLOX). Proc Am Soc Clin Oncol. 2003;22:294. Abstract 1181.

Thomas RR, Quinn MG, Schuler B, Grem JL. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer. 2003; 97:2301-2307.

Twelves C, Boyer M, Findlay M, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer. 2001;37:597-604.

Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001; 19:4097-4106.

Van Cutsem E, Twelves C, Tabernero J, et al. XELOX: Mature results of a multinational, phase II trial of capecitabine plus oxaliplatin, an effective 1st line option for patients (pts) with metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol. 2003;22:255. Abstract 1023.

Wilkes GM. New therapeutic options in colon cancer: focus on oxaliplatin. Clin J Oncol Nurs. 2002;6:131-137.